Show simple item record

dc.creatorPrado J,Valeria
dc.creatorGiangrieco O,Marcela
dc.creatorDurán T,Claudia
dc.creatorOjeda S,Alicia
dc.creatorFlaskamp von F,Renate
dc.date2000-12-01
dc.date.accessioned2020-02-17T15:25:56Z
dc.date.available2020-02-17T15:25:56Z
dc.identifierhttps://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872000001200003
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/126424
dc.descriptionBackground: Respiratory pathogens are becoming increasingly resistant to antimicrobials. A new group of drugs, called respiratory quinolones have been synthesized to overcome this problem. Aim: To study the in vitro susceptibility of respiratory pathogens to old and new antimicrobials. Material and methods: Forty five strains of S pneumoniae, 44 strains of H influenzae, 21 strains of M catarrhalis, 10 strains of methicillin susceptible S aureus and 20 strains of methicillin resistant S aureus were studied. All were isolated from community acquired respiratory infections during 1999. Minimal inhibitory concentrations of moxifloxacin, amoxicilin, amoxicilin/clavulanic acid, clarithromycin, azithromycin, ciprofloxacin and levofloxacin were determined using the Etest method. Betalactamase production by H influenzae and M catarrhalis was also studied. Results: S pneumoniae strains were 100% susceptible to quinolones and cotrimoxazole, 2% were resistant to macrolides, 11% were resistant to amoxicilin/clavulanic acid and 47% were resistant to cefuroxime. H influenzae was 100% susceptible to quinolones, azithromycin and amoxicilin/clavulanic acid. There was a 53% resistance to cotrimoxazole, 21% to amoxicilin, 9% to clarithromycin and 7% to cefuroxime. M catarrhalis was 100% susceptible to quinolones and 100% resistant to amoxicilin, 5% resistant to macrolides, 14% resistant to amoxicilin/clavulanic acid, 20% to cefuroxime and 30% to cotrimoxazole. Methicilline susceptible S aureus was susceptible to all antimicrobials and methicillin resistant S aureus was resistant to all. Conclusions: Moxifloxacin and the new respiratory quinolones can be useful in the treatment of respiratory infections (Rev Méd Chile 2000; 128: 1319-26).
dc.formattext/html
dc.languagees
dc.publisherSociedad Médica de Santiago
dc.relation10.4067/S0034-98872000001200003
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourceRevista médica de Chile v.128 n.12 2000
dc.subjectAnti-Infective Agents
dc.subjectQuinolones
dc.subjectRespiratory Tract Infections
dc.titleActividad comparativa in vitro de moxifloxacina y otros antimicrobianos frente a patógenos respiratorios


This item appears in the following Collection(s)

Show simple item record